Cargando…

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations

The extensive drug resistance requires rational approaches to design personalized combinatorial treatments that exploit patient-specific therapeutic vulnerabilities to selectively target disease-driving cell subpopulations. To solve the combinatorial explosion challenge, we implemented an effective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ianevski, Aleksandr, Lahtela, Jenni, Javarappa, Komal K., Sergeev, Philipp, Ghimire, Bishwa R., Gautam, Prson, Vähä-Koskela, Markus, Turunen, Laura, Linnavirta, Nora, Kuusanmäki, Heikki, Kontro, Mika, Porkka, Kimmo, Heckman, Caroline A., Mattila, Pirkko, Wennerberg, Krister, Giri, Anil K., Aittokallio, Tero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895436/ https://www.ncbi.nlm.nih.gov/pubmed/33608276 http://dx.doi.org/10.1126/sciadv.abe4038

Ejemplares similares

A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening
por: Gupta, Abhishekh, et al.
Publicado: (2020)

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
por: Yadav, Bhagwan, et al.
Publicado: (2014)

RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
por: Adnan Awad, Shady, et al.
Publicado: (2020)

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2023)

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
por: Gautam, Prson, et al.
Publicado: (2016)

Drug Target Commons 2.0: a community platform for systematic analysis of drug–target interaction profiles
por: Tanoli, ZiaurRehman, et al.
Publicado: (2018)

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
por: Malani, Disha, et al.
Publicado: (2022)

What is synergy? The Saariselkä agreement revisited
por: Tang, Jing, et al.
Publicado: (2015)

Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data
por: Potdar, Swapnil, et al.
Publicado: (2023)

Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia
por: White, Brian S., et al.
Publicado: (2021)

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
por: Eldfors, S, et al.
Publicado: (2017)

TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples
por: He, Liye, et al.
Publicado: (2015)

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
por: Yadav, Bhagwan, et al.
Publicado: (2015)

Corrigendum to “Searching for drug synergy in complex dose–response landscapes using an interaction potency model” [Comput. Struct. Biotechnol. J. 13 (2015) 504–513]
por: Yadav, Bhagwan, et al.
Publicado: (2017)

Breeze: an integrated quality control and data analysis application for high-throughput drug screening
por: Potdar, Swapnil, et al.
Publicado: (2020)

Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach
por: Ali, Mehreen, et al.
Publicado: (2018)

An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia
por: Kong, Weikaixin, et al.
Publicado: (2022)

Improved detection of differentially represented DNA barcodes for high‐throughput clonal phenomics
por: Akimov, Yevhen, et al.
Publicado: (2020)

Multi‐modal meta‐analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor
por: Jaiswal, Alok, et al.
Publicado: (2021)

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2022)

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
por: Pietarinen, Paavo O., et al.
Publicado: (2017)

Systematic identification of feature combinations for predicting drug response with Bayesian multi-view multi-task linear regression
por: Ammad-ud-din, Muhammad, et al.
Publicado: (2017)

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
por: Pietarinen, P O, et al.
Publicado: (2015)

Exploration of databases and methods supporting drug repurposing: a comprehensive survey
por: Tanoli, Ziaurrehman, et al.
Publicado: (2020)

Systematic mapping of cancer cell target dependencies using high-throughput drug screening in triple-negative breast cancer
por: Wang, Tianduanyi, et al.
Publicado: (2020)

Multiobjective optimization identifies cancer-selective combination therapies
por: Pulkkinen, Otto I., et al.
Publicado: (2020)

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
por: Malani, D, et al.
Publicado: (2017)

SynergyFinder 2.0: visual analytics of multi-drug combination synergies
por: Ianevski, Aleksandr, et al.
Publicado: (2020)

Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data
por: Ianevski, Aleksandr, et al.
Publicado: (2022)

SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples
por: Ianevski, Aleksandr, et al.
Publicado: (2022)

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2020)

Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways
por: Tang, Jing, et al.
Publicado: (2013)

Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells
por: Jaiswal, Alok, et al.
Publicado: (2017)

Novel Screening Method Identifies PI3Kα, mTOR, and IGF1R as Key Kinases Regulating Cardiomyocyte Survival
por: Elmadani, Manar, et al.
Publicado: (2019)

SynergyFinder: a web application for analyzing drug combination dose–response matrix data
por: Ianevski, Aleksandr, et al.
Publicado: (2017)

SynergyFinder: a web application for analyzing drug combination dose–response matrix data
por: Ianevski, Aleksandr, et al.
Publicado: (2020)

Pancreatic Cancer Organoids in the Field of Precision Medicine: A Review of Literature and Experience on Drug Sensitivity Testing with Multiple Readouts and Synergy Scoring
por: Mäkinen, Lotta, et al.
Publicado: (2022)

Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer
por: Tang, Jing, et al.
Publicado: (2019)

Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets
por: Adnan-Awad, Shady, et al.
Publicado: (2020)

Identification of novel regulators of STAT3 activity
por: Parri, Elina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8fhrpvbfh49rjphrd7rt69voh6